Edge Wealth Management LLC Avadel Pharmaceuticals PLC Transaction History

Edge Wealth Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	SELL	$12.55 - $17.22 $1.38 Million - $1.89 Million	-110,000 Reduced 73.33%	40,000 $675,000
Q2 2023 Jul 13, 2023	SELL	$8.48 - $16.48 $169,600 - $329,600	-20,000 Reduced 11.76%	150,000 $2.47 Million
Q4 2022 Jan 25, 2023	BUY	$5.02 - $10.0 $70,280 - $140,000	14,000 Added 8.97%	170,000 $0
Q2 2022 Jul 22, 2022	BUY	$1.07 - $6.95 $11,770 - $76,450	11,000 Added 7.59%	156,000 $381,000
Q3 2021 Oct 13, 2021	BUY	$6.49 - $9.91 $97,350 - $148,650	15,000 Added 11.54%	145,000 $1.42 Million
Q1 2021 Apr 09, 2021	BUY	$6.61 - $10.07 $198,300 - $302,100	30,000 Added 30.0%	130,000 $1.18 Million
Q4 2020 Jan 19, 2021	BUY	$5.03 - $7.95 $201,200 - $318,000	40,000 Added 66.67%	100,000 $679,000
Q3 2020 Oct 21, 2020	BUY	$5.02 - $8.98 $301,200 - $538,800	60,000 New	60,000 $302,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Edge Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on Edge Wealth Management LLC with notifications on news.